Follow The Filings

ALDX Aldeyra Therapeutics

Aldeyra Therapeutics earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.09 — —
Rev — — —

Insider trades

Open-market buys and sales by ALDX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ALDX insider trades
  • $524K bought by 3 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Todd C Brady CEO
    Buy
    $418K 250,000 shares at $1.67 +17% to stake
    Traded Jun 3 Filed Jun 5
    ↗
  2. Richard Douglas Director
    Buy
    $98K 70,000 shares at $1.40 +56% to stake
    Traded Mar 19 Filed Mar 20
    ↗
  3. Michael Alfieri Principal Financial Officer
    Buy
    $7,100 5,000 shares at $1.42 +200% to stake
    Traded Mar 18 Filed Mar 19
    ↗

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 8.01 Filing Doc
8-K 5.02,5.07,7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 7.01,9.01 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02 Filing Doc
8-K 8.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-K Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 5.02 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 9.01 Filing Doc

Source: SEC EDGAR submissions, updated 15 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf